GlassScriptPhysician profile
Precious M Simataa
NPI 1326640640
$5,328.15
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,678 · 2022: $3,178 · 2023: $403 · 2024: $68.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $681.88 | 2021-2024 | |
| Livanova USA, INC. | $444.40 | 2021-2022 | |
| Biogen, INC. | $290.19 | 2021-2023 | Vumerity, Tysabri |
| Emd Serono, INC. | $282.52 | 2022 | |
| Neurocrine Biosciences, INC. | $270.10 | 2021-2023 | Ongentys, Ingrezza |
| Jazz Pharmaceuticals INC. | $264.12 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $208.81 | 2021 | |
| Horizon Therapeutics Plc | $200.08 | 2022 | |
| Novartis Pharmaceuticals Corporation | $194.33 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $184.82 | 2021-2022 | |
| Ucb, INC. | $179.12 | 2021-2023 | Briviact |
| Amgen INC. | $172.63 | 2021-2023 | Aimovig |
| Biohaven Pharmaceutical Holding Company LTD. | $172.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $168.47 | 2021-2022 | |
| Eisai INC. | $151.09 | 2021-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Precious Simataa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.